GlassScriptPhysician profile
Brittany B Click
NPI 1245670348
$4,105.75
in general payments reported to CMS, 2019-2025
37 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $968 · 2023: $191 · 2024: $1,137 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,964.41 |
| Education | $173.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $682.97 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $550.86 | 2021-2025 | |
| Genzyme Corporation | $263.83 | 2021-2025 | |
| Madrigal Pharmaceuticals | $249.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $241.16 | 2021-2025 | Omvoh, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.89 | 2021-2025 | Xifaxan |
| Novo Nordisk INC | $230.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.64 | 2024-2025 | Entyvio, Glassia, Aralast |
| Astrazeneca Pharmaceuticals LP | $152.40 | 2021-2024 | Tagrisso |
| Grifols USA, LLC | $131.50 | 2024-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $125.00 | 2023 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $114.20 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $96.77 | 2021-2025 | Zerbaxa |
| Astellas Pharma US INC | $74.07 | 2021 | |
| Phathom Pharmaceuticals, INC. | $68.63 | 2025 | Voquezna |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $68.39 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $64.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $55.76 | 2021 | |
| Intercept Pharmaceuticals, INC. | $47.49 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $43.96 | 2024 | |
| Braintree Laboratories, INC. | $41.62 | 2025 | Suflave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.71 | 2021 | |
| Evoke Pharma, INC. | $36.91 | 2023-2024 | Gimoti |
| Gilead Sciences, INC. | $36.78 | 2024-2025 | |
| Harmony Biosciences LLC | $36.10 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $33.82 | 2021 | |
| Esperion Therapeutics, INC. | $31.43 | 2021 | |
| Galderma Laboratories, L.P. | $28.98 | 2021 | |
| Amgen INC. | $22.05 | 2021 | |
| Amneal Pharmaceuticals LLC | $21.41 | 2024 | Rytary |
| Jazz Pharmaceuticals INC. | $19.44 | 2021 | |
| Ferring Pharmaceuticals INC. | $18.63 | 2024 | Rebyota |
| Baxter Healthcare | $18.09 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Olympus America INC. | $17.61 | 2024 | Evis Exera III Colonovideoscope |
| Pfizer INC. | $16.77 | 2025 | |
| Antares Pharma, INC. | $16.28 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Click listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.